Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **E3 ligase–target protein interface** is the region where an **E3 ubiquitin ligase enzyme** physically interacts with a specific substrate protein to catalyze the transfer of ubiquitin, marking the substrate for degradation or functional modification[1][3][5][7]. This interface confers substrate specificity in the ubiquitination pathway, playing a central role in cellular protein turnover, signal transduction, cell cycle, and stress responses. Current drug discovery efforts, notably PROTAC and molecular glue technologies, focus on modulating this interface to induce selective degradation of disease-related proteins, presenting new opportunities and challenges in drug development[4][6][8].
Induced ubiquitination and degradation of specific target proteins through recruitment to E3 ligases - Inhibition or modulation of E3–substrate recognition (blocking protein degradation pathways)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin E3 ligase–target protein interface.